- Mar 19, 2016
- 4,195
- 1,972
- Country
- United States
- Gender
- Male
- Faith
- SDA
- Marital Status
- Married
Finally somebody has caught some common sense
"Because of conflicting data on the treatments by the principal authors, “We find that the available data does not justify filing disciplinary actions against physicians simply because they prescribe ivermectin or hydroxychloroquine to prevent or treat COVID-19,” the opinion said.
The office of AG even attacked the company, Merck, on their agenda.
Why would ivermectin’s original patent holder go out of its way to question this medicine by creating the impression that it might not be safe? There are at least two plausible reasons. First, ivermectin is no longer under patent, so Merck does not profit from it anymore. That likely explains why Merck declined to “conductI] clinical trials” on ivermectin and COVID-19 when given the chance.
Second, Merck has a significant financial interest in the medical profession rejecting ivermectin as an early treatment for
COVID-19. “[The U.S. government has agreed to pay [Merck] about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.”"
Nebraska AG Issues Opinion on Doctors Prescribing HCQ and Ivermectin for COVID Treatment Will Not Face Punishment
"Because of conflicting data on the treatments by the principal authors, “We find that the available data does not justify filing disciplinary actions against physicians simply because they prescribe ivermectin or hydroxychloroquine to prevent or treat COVID-19,” the opinion said.
The office of AG even attacked the company, Merck, on their agenda.
Why would ivermectin’s original patent holder go out of its way to question this medicine by creating the impression that it might not be safe? There are at least two plausible reasons. First, ivermectin is no longer under patent, so Merck does not profit from it anymore. That likely explains why Merck declined to “conductI] clinical trials” on ivermectin and COVID-19 when given the chance.
Second, Merck has a significant financial interest in the medical profession rejecting ivermectin as an early treatment for
COVID-19. “[The U.S. government has agreed to pay [Merck] about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.”"
Nebraska AG Issues Opinion on Doctors Prescribing HCQ and Ivermectin for COVID Treatment Will Not Face Punishment